New hope for frail hodgkin lymphoma patients ineligible for standard care
NCT ID NCT07275216
Summary
This study is testing a combination of immunotherapy and chemotherapy for frail adults newly diagnosed with Hodgkin lymphoma who are not healthy enough for the usual first-line treatment. The goal is to see if this alternative approach can safely and effectively control the cancer. Researchers will measure how well the treatment works and monitor side effects in about 23 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.